research BMP Signaling in the Hair Follicle Stem Cell Niche Regulates Hair Growth and Skin Pigmentation
BMP signaling controls hair growth and skin color.
Search
for
Sort by
Research
150-180 / 272 results 
research Medications
Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
research Methotrexate Dose Has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial
Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
research British Society for Dermatopathology 2011 Findings
Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.
research An Overview of Alopecia Areata: Etiopathogenesis, Diagnosis, and Management
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Current Best Evidence in Pigmentary Dermatology
Several treatments are effective for pigmentary disorders like vitiligo and melasma.
research Particulate Matter Induces Inflammatory Response in Human Outer Root Sheath Cells via Oxidative Stress-Dependent MAPK and JAK-STAT Signaling Pathways
Particulate matter causes inflammation in hair cells, potentially harming hair growth.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Evaluation of the Level of Serum Interleukins (IL-2, IL-4, IL-15, and IL-17) and Its Relationship with Disease Severity in Patients with Alopecia Areata
Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Efficacy and Safety of Tofacitinib Therapy in Asian Patients with Severe Alopecia Areata
Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
research Alopecia Areata: Case Report and Review of Pathophysiology and Treatment with JAK Inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Interleukin-15 Is a Hair Follicle Immune Privilege Guardian
Interleukin-15 can help hair growth and protect hair follicles.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Peripheral Neuropathy Associated with Tofacitinib Use in Alopecia Universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment
Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.
research Effects of Natural Herbal Marker Compounds on Human Dermal Papilla Cell Growth Regulation
Four natural compounds were found to promote hair growth effectively.
research Overview Of Alopecia Areata For Managed Care And Payer Stakeholders In The United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research IKZF1 and IKAROS Overexpression Contributes to the Pathogenesis of Alopecia Areata
Too much IKZF1 and Ikaros protein may cause alopecia areata.
research IL-9/IL-9R Signaling as a Novel Regulator of Human Hair Follicle Growth and Immune Privilege
IL-9/IL-9R signaling can negatively affect human hair growth and may be a target for treating hair loss conditions.